20170-32-5

Usage

Uses

Used in Pharmaceutical Industry:
3-(3,5-Di-tert-butyl-4-hydroxyphenyl)propionic acid is used as an active pharmaceutical intermediate for the synthesis of various drugs and pharmaceutical compounds. Its antioxidant properties make it a valuable component in the development of medications that require stabilization against oxidation.
Used in Antioxidant Synthesis:
3-(3,5-Di-tert-butyl-4-hydroxyphenyl)propionic acid is used as a key component in the synthesis of antioxidants, particularly those with a phenolic structure. These antioxidants are widely used as additives in the plastics, rubber, and coatings industries to prevent degradation caused by oxidation.
Used in Lubricating Oil Industry:
3-(3,5-Di-tert-butyl-4-hydroxyphenyl)propionic acid is used as an antioxidant group to modify esters, which are then utilized in the lubricating oil industry. The modified esters provide both antioxidant and lubricant functions, making them highly valuable in this application.
Used in Cutting Compound Industry:
Similarly, the modified esters derived from 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionic acid are also used in the cutting compound industry. The dual functionality of these compounds as antioxidants and lubricants enhances their performance and extends the life of cutting tools.

Safely

The toxicity of 3-(3,5-di-tert-butyl-4- hydroxyphenyl)propanoic acid, esters with C13-C15 branched and linear alcohols has been tested by EFSA. And this scientific opinion of EFSA deals with the risk assessment of the additive, 3-(3,5-di-tert-butyl-4- hydroxyphenyl)propanoic acid, esters with C13-C15 branched and linear alcohols, CAS No. 171090- 93-0, REF. No. 47060 for which the CEF Panel concluded that there is no safety concern for the consumer if the substance is used only in polyolefins in contact with foods other than fatty/highalcoholic and dairy products and its migration does not exceed 0.05 mg/kg food.

InChI:InChI=1/C17H26O3/c1-16(2,3)12-9-11(7-8-14(18)19)10-13(15(12)20)17(4,5)6/h9-10,20H,7-8H2,1-6H3,(H,18,19)/p-1

Upstream product

• 29027-77-8 3-(3,5-di-tert-butyl-4-hydroxy-phenyl)-propionitrile 
• 22014-01-3 3-(3,5-di-tert-butyl-4-hydroxyphenyl)prop-2-enoic acid 
• 82304-66-3 6,8-di-tert-butylspiro<4.5>-deca-1-oxa-5,8-diene-2,7-dione 
• 128-39-2 2,6-di-tert-butylphenol 
• 6386-38-5 methyl 3-(4-hydroxy-3,5-di-tert-butyl)phenylpropanoate 
• 26347-98-8 pentaerythritol ester of 4-hydroxy-3,5-di-tert-butylphenylpropionic acid 
• 95602-92-9 3,5-di-tert-butyl-4-hydroxycinnamic acid 

Downstream Products

• 42293-41-4 β-(4-hydroxy-3,5-di-tert-butylphenyl) propionic acid N-phenylamide 
• 82612-18-8 β-(4-hydroxy-3,5-di-tert-butylphenyl) propionic acid anhydride 
• 102-07-8 bis(diphenyl)urea 
• 6386-38-5 methyl 3-(4-hydroxy-3,5-di-tert-butyl)phenylpropanoate 
• 36294-23-2 4-(3-hydroxypropyl)-2,6-di-tert-butylphenol 
• 515815-37-9 3-(3,5-di-tert-butyl-4-hydroxyphenyl)-N-(3-{[imino(thien-2-yl)methyl]amino}benzyl)propanamide 
• 1707-75-1 2,2-diphenyl-1-picrylhydrazine 
• 93543-10-3 4-(3-bromopropyl)-2,6-di-t-butylphenol 
• 428861-65-8 4-[3-(4-amino-phenoxy)-propyl]-2,6-di-tert-butyl-phenol 
• 34249-71-3 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propanamide 
• 19510-14-6 γ-(4-hydroxy-3,5-di-tert-butylphenyl)propylamine 
• 57529-36-9 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propyl cyanide 

Relevant academic research and scientific papers

Hindered phenol and acylamino intramolecular composite difunctional antioxygen and synthesis method thereof

The invention belongs to the technical field of antioxygens, and particularly relates to a hindered phenol and acylamino intramolecular composite difunctional antioxygen and a synthesis method thereof. The hindered phenol and acylamino intramolecular composite difunctional antioxygen is prepared through the mode that firstly, ethanediamine, methyl alcohol and methyl acrylate are prepared into an ethanediamine dendritic molecule framework, and then the end group of the ethanediamine dendritic molecule framework is subjected to DtBHP closing. The antioxygen forms stable free radicals to end a chain reaction by capturing generated free radicals, the free radicals can be directly, effectively and quickly captured, and the antioxygen is high in antioxygenic capacity.

A method for preparing an antioxidant

The invention provides a preparation method for an antioxidant. The method includes: subjecting a compound shown as formula (III) and a compound shown s formula (IV) to dehydration reaction in the presence of an organic solvent. The method is characterized in that in the dehydration reaction process, the reaction generated water and part of the organic solvent are separated from the reaction system, and water division treatment is carried out, then the water-containing organic solvent subjected to water division treatment contacts a first dehydrating agent, and the organic solvent obtained after contact is returned to the reaction system. Specifically, n is 1 or 2, x is 1 or 2, y is an integer of 0-6, R1 and R2 are not a straight chain or branched chain alkyl group with a hydrogen atom or carbon atom number of 1-6 at the same time, and R3 and R4 are not a straight chain or branched chain alkyl group with a hydrogen atom or carbon atom number of 1-6 at the same time. By adopting the method provided by the invention to prepare the antioxidant, the dehydration effect of the reaction system can be enhanced, and accordingly the reaction efficiency and product yield can be enhanced. (formula III and formula IV).

Discovery of a negative allosteric modulator of GABAB receptors

Initialized from the scaffold of CGP7930, an allosteric agonist of GABAB receptors, a series of noncompetitive antagonists were discovered. Among these compounds, compounds 3, 6, and 14 decreased agonist GABA-induced maximal effect of IP3 production in HEK293 cells overexpressing GABAB receptors and Gqi9 proteins without changing the EC50. Compounds 3, 6, and 14 not only inhibited agonist baclofen-induced ERK1/2 phosphorylation but also blocked CGP7930-induced ERK1/2 phosphorylation in HEK293 cells overexpressing GABAB receptors. The results suggested that compounds 3, 6, and 14 are negative allosteric modulators of GABAB receptors. The representative compound 14 decreased GABA-induced IP3 production with IC50 of 37.9 μM and had no effect on other GPCR Class C members such as mGluR1, mGluR2, and mGluR5. Finally, we showed that compound 14 did not bind to the orthosteric binding sites of GABAB receptors, demonstrating that compound 14 negatively modulated GABAB receptors activity as a negative allosteric modulator.

Long chain (4-hydroxyphenyl) propanoate stabilizers

Long chain (4-hydroxyphenyl) propanoate derivatives of the formula STR1 are effective in stabilizing organic materials against oxidative and thermal degradation.